Beijing Horicin Biotechnology

Horicin is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative gene therapies for rare and chronic diseases. Founded by renowned scientist Professor Rao Yi, the company focuses on liver-targeted treatments using its proprietary adeno-associated virus (AAV) vector platform. Its lead program, GS101, is an AAV-based gene therapy for Hemophilia A that has successfully entered clinical trials. Horicin operates an integrated model with in-house R&D and GMP manufacturing capabilities to support its pipeline from discovery through commercialization. The company aims to provide one-time curative treatments for genetic disorders that currently require lifelong management.